Ocular Historical Balance Sheet

OCUL Stock

USD 9.77 0.12 1.21%

Trend analysis of Ocular Therapeutix balance sheet accounts such as Total Current Liabilities of 36.6 M provides information on Ocular Therapeutix's total assets, liabilities, and equity, which is the actual value of Ocular Therapeutix to its prevalent stockholders. By breaking down trends over time using Ocular Therapeutix balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Ocular Therapeutix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ocular Therapeutix is a good buy for the upcoming year.

Ocular Therapeutix Inventory

2.42 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

About Ocular Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ocular Therapeutix at a specified time, usually calculated after every quarter, six months, or one year. Ocular Therapeutix Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ocular Therapeutix and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ocular currently owns. An asset can also be divided into two categories, current and non-current.

Ocular Therapeutix Balance Sheet Chart

At this time, Ocular Therapeutix's Non Currrent Assets Other are quite stable compared to the past year. Long Term Debt is expected to rise to about 78.7 M this year, although the value of Other Liabilities will most likely fall to about 18.3 M.

Total Assets Short Long Term Debt Total Other Current Liab Liabilities And Stockholders Equity Total Liab Accumulated Other Comprehensive Income

Add Fundamental

Total Assets

Total assets refers to the total amount of Ocular Therapeutix assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ocular Therapeutix books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Accumulated Other Comprehensive Income

Gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized.

Most accounts from Ocular Therapeutix's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.At this time, Ocular Therapeutix's Non Currrent Assets Other are quite stable compared to the past year. Long Term Debt is expected to rise to about 78.7 M this year, although the value of Other Liabilities will most likely fall to about 18.3 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	59.0M	64.3M	83.4M	87.6M
Total Assets	204.9M	149.3M	252.1M	126.8M

Short Long Term Debt Total Total Assets

Ocular Therapeutix balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.79	0.76	0.82	0.77	0.77	0.72	-0.87	-0.84	0.7	0.9	0.68	0.2	0.38	0.76	0.99	0.77	0.88	0.66	0.89	0.84	0.75	0.63	0.92	0.41	0.62
Short Long Term Debt Total	0.79		0.95	0.95	0.66	0.52	0.86	-0.69	-0.98	0.8	0.88	0.82	0.29	0.16	0.99	0.73	0.91	0.87	0.56	0.88	0.97	0.66	0.92	0.87	0.12	0.62
Other Current Liab	0.76	0.95		0.98	0.66	0.41	0.75	-0.7	-0.96	0.78	0.86	0.72	0.24	0.04	0.96	0.69	0.98	0.85	0.52	0.87	0.96	0.62	0.92	0.87	0.09	0.54
Total Current Liabilities	0.82	0.95	0.98		0.67	0.56	0.8	-0.78	-0.98	0.8	0.91	0.76	0.24	0.16	0.93	0.76	0.96	0.88	0.58	0.91	0.97	0.69	0.89	0.9	0.17	0.57
Total Stockholder Equity	0.77	0.66	0.66	0.67		0.41	0.51	-0.61	-0.68	0.65	0.68	0.51	0.29	0.23	0.68	0.79	0.61	0.68	0.07	0.72	0.75	0.2	0.58	0.81	0.5	0.88
Other Liab	0.77	0.52	0.41	0.56	0.41		0.5	-0.85	-0.57	0.34	0.77	0.47	0.12	0.66	0.43	0.8	0.44	0.55	0.77	0.68	0.56	0.78	0.31	0.7	0.44	0.32
Property Plant And Equipment Net	0.72	0.86	0.75	0.8	0.51	0.5		-0.5	-0.89	0.91	0.68	0.98	0.46	0.38	0.83	0.63	0.68	0.91	0.49	0.67	0.85	0.6	0.74	0.63	0.08	0.67
Net Debt	-0.87	-0.69	-0.7	-0.78	-0.61	-0.85	-0.5		0.73	-0.44	-0.95	-0.47	-0.15	-0.41	-0.65	-0.88	-0.74	-0.66	-0.75	-0.9	-0.75	-0.79	-0.6	-0.91	-0.36	-0.36
Retained Earnings	-0.84	-0.98	-0.96	-0.98	-0.68	-0.57	-0.89	0.73		-0.86	-0.89	-0.87	-0.37	-0.27	-0.96	-0.77	-0.92	-0.93	-0.58	-0.9	-0.99	-0.69	-0.89	-0.87	-0.15	-0.64
Accounts Payable	0.7	0.8	0.78	0.8	0.65	0.34	0.91	-0.44	-0.86		0.62	0.9	0.46	0.26	0.79	0.61	0.71	0.93	0.26	0.69	0.85	0.41	0.67	0.62	0.11	0.77
Cash	0.9	0.88	0.86	0.91	0.68	0.77	0.68	-0.95	-0.89	0.62		0.64	0.22	0.33	0.85	0.88	0.87	0.79	0.72	0.97	0.9	0.79	0.79	0.97	0.29	0.49
Non Current Assets Total	0.68	0.82	0.72	0.76	0.51	0.47	0.98	-0.47	-0.87	0.9	0.64		0.62	0.49	0.8	0.59	0.63	0.88	0.42	0.64	0.83	0.54	0.72	0.59	0.04	0.69
Non Currrent Assets Other	0.2	0.29	0.24	0.24	0.29	0.12	0.46	-0.15	-0.37	0.46	0.22	0.62		0.7	0.31	0.14	0.13	0.39	-0.06	0.21	0.38	0.0	0.29	0.15	-0.16	0.47
Other Assets	0.38	0.16	0.04	0.16	0.23	0.66	0.38	-0.41	-0.27	0.26	0.33	0.49	0.7		0.11	0.39	-0.02	0.32	0.28	0.25	0.26	0.29	0.01	0.24	0.2	0.37
Long Term Debt	0.76	0.99	0.96	0.93	0.68	0.43	0.83	-0.65	-0.96	0.79	0.85	0.8	0.31	0.11		0.69	0.91	0.86	0.5	0.86	0.96	0.6	0.94	0.85	0.1	0.63
Cash And Short Term Investments	0.99	0.73	0.69	0.76	0.79	0.8	0.63	-0.88	-0.77	0.61	0.88	0.59	0.14	0.39	0.69		0.71	0.81	0.64	0.87	0.79	0.72	0.57	0.92	0.49	0.6
Net Receivables	0.77	0.91	0.98	0.96	0.61	0.44	0.68	-0.74	-0.92	0.71	0.87	0.63	0.13	-0.02	0.91	0.71		0.82	0.59	0.9	0.91	0.69	0.86	0.87	0.09	0.42
Common Stock Shares Outstanding	0.88	0.87	0.85	0.88	0.68	0.55	0.91	-0.66	-0.93	0.93	0.79	0.88	0.39	0.32	0.86	0.81	0.82		0.53	0.85	0.92	0.66	0.71	0.79	0.16	0.68
Non Current Liabilities Total	0.66	0.56	0.52	0.58	0.07	0.77	0.49	-0.75	-0.58	0.26	0.72	0.42	-0.06	0.28	0.5	0.64	0.59	0.53		0.65	0.51	0.99	0.44	0.6	0.1	-0.09
Other Current Assets	0.89	0.88	0.87	0.91	0.72	0.68	0.67	-0.9	-0.9	0.69	0.97	0.64	0.21	0.25	0.86	0.87	0.9	0.85	0.65		0.91	0.73	0.76	0.95	0.26	0.53
Other Stockholder Equity	0.84	0.97	0.96	0.97	0.75	0.56	0.85	-0.75	-0.99	0.85	0.9	0.83	0.38	0.26	0.96	0.79	0.91	0.92	0.51	0.91		0.63	0.89	0.9	0.23	0.69
Total Liab	0.75	0.66	0.62	0.69	0.2	0.78	0.6	-0.79	-0.69	0.41	0.79	0.54	0.0	0.29	0.6	0.72	0.69	0.66	0.99	0.73	0.63		0.53	0.69	0.12	0.05
Property Plant And Equipment Gross	0.63	0.92	0.92	0.89	0.58	0.31	0.74	-0.6	-0.89	0.67	0.79	0.72	0.29	0.01	0.94	0.57	0.86	0.71	0.44	0.76	0.89	0.53		0.78	0.06	0.51
Total Current Assets	0.92	0.87	0.87	0.9	0.81	0.7	0.63	-0.91	-0.87	0.62	0.97	0.59	0.15	0.24	0.85	0.92	0.87	0.79	0.6	0.95	0.9	0.69	0.78		0.42	0.59
Short Term Debt	0.41	0.12	0.09	0.17	0.5	0.44	0.08	-0.36	-0.15	0.11	0.29	0.04	-0.16	0.2	0.1	0.49	0.09	0.16	0.1	0.26	0.23	0.12	0.06	0.42		0.32
Common Stock	0.62	0.62	0.54	0.57	0.88	0.32	0.67	-0.36	-0.64	0.77	0.49	0.69	0.47	0.37	0.63	0.6	0.42	0.68	-0.09	0.53	0.69	0.05	0.51	0.59	0.32

Click cells to compare fundamentals

Ocular Therapeutix Account Relationship Matchups

Ocular Therapeutix balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	78.7M	261.9M	204.9M	149.3M	252.1M	126.8M
Short Long Term Debt Total	59.3M	58.4M	59.0M	64.3M	83.4M	87.6M
Other Current Liab	7.6M	12.9M	18.5M	22.5M	27.1M	28.4M
Total Current Liabilities	12.0M	26.7M	26.3M	31.4M	34.9M	36.6M
Total Stockholder Equity	(3.6M)	76.1M	88.0M	35.4M	91.1M	95.7M
Other Liab	12.1M	110.3M	33.2M	19.8M	22.8M	18.3M
Property Plant And Equipment Net	16.8M	13.9M	11.8M	17.9M	18.2M	10.0M
Net Debt	4.9M	(169.6M)	(105.2M)	(38.0M)	(112.4M)	(106.8M)
Retained Earnings	(383.6M)	(539.3M)	(545.8M)	(616.8M)	(697.6M)	(662.7M)
Accounts Payable	3.3M	2.7M	4.6M	5.1M	4.4M	3.0M
Cash	54.4M	228.1M	164.2M	102.3M	195.8M	205.6M
Non Current Assets Total	18.6M	15.7M	13.6M	19.7M	19.8M	11.8M
Other Assets	1.6M	6.6M	1.8M	7.6M	1.0	0.95
Long Term Debt	49.3M	41.2M	51.4M	54.0M	74.9M	78.7M
Cash And Short Term Investments	54.4M	228.1M	164.2M	102.3M	195.8M	103.6M
Net Receivables	2.5M	12.3M	21.1M	21.3M	26.2M	27.5M
Common Stock Shares Outstanding	45.3M	60.8M	82.2M	76.9M	85.6M	44.2M
Liabilities And Stockholders Equity	78.7M	261.9M	204.9M	149.3M	252.1M	126.8M
Non Current Liabilities Total	70.3M	159.1M	90.6M	82.5M	126.0M	69.6M
Other Current Assets	2.2M	8.0M	9.5M	4.0M	7.9M	8.3M
Other Stockholder Equity	380.0M	615.3M	633.8M	652.2M	788.7M	828.1M
Total Liab	82.4M	185.8M	116.9M	113.9M	160.9M	86.2M
Property Plant And Equipment Gross	16.8M	13.9M	11.8M	17.9M	38.5M	40.4M
Total Current Assets	60.2M	246.2M	191.3M	129.6M	232.2M	243.8M
Property Plant Equipment	10.2M	8.1M	11.8M	9.9M	11.3M	7.1M
Net Tangible Assets	(3.6M)	76.1M	88.0M	35.4M	31.8M	40.7M
Retained Earnings Total Equity	(383.6M)	(539.3M)	(545.8M)	(616.8M)	(555.2M)	(527.4M)
Long Term Debt Total	49.3M	41.2M	51.4M	54.0M	62.1M	33.7M
Capital Surpluse	380.0M	615.3M	633.8M	652.2M	750.0M	424.2M
Inventory	954K	1.2M	1.3M	2.0M	2.3M	2.4M
Deferred Long Term Liab	12.1M	98.3M	20.2M	6.4M	7.3M	6.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:

How To Invest In Ocular

Details

Is Ocular Stock a good investment?

Details

What is Ocular Therapeutix's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.29)

Revenue Per Share

0.529

Quarterly Revenue Growth

0.083

Return On Assets

(0.22)

Return On Equity

(0.73)

The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ocular Historical Balance Sheet

Ocular Therapeutix Inventory

2.42 Million

About Ocular Balance Sheet Analysis

Ocular Therapeutix Balance Sheet Chart

Total Assets

Liabilities And Stockholders Equity

Total Liab

Accumulated Other Comprehensive Income

Ocular Therapeutix balance sheet Correlations

Ocular Therapeutix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ocular Therapeutix balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Total Assets
Long Term Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Non Current Liabilities Total
Total Current Liabilities	+ 0.98	Other Current Liab
Net Receivables	+ 0.98	Other Current Liab
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net

Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Retained Earnings	- 0.98	Short Long Term Debt Total
Long Term Debt	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Other Current Liab
Cash	- 0.95	Net Debt